SCHEMBL27218707

SCHEMBL27218707

Cc1ccc(-c2noc(CCSc3nc(O)cc(C(F)(F)F)n3)n2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ LMNA P02545 3/20 0.48
▸ HTT P42858 3/20 0.48
▸ NPC1 O15118 2/20 0.48
▸ RAB9A P51151 2/20 0.48
▸ HDAC2 Q92769 2/20 0.47
▸ HDAC8 Q9BY41 2/20 0.47
▸ MAPT P10636 7/20 0.44
▸ TDP1 Q9NUW8 3/20 0.43
▸ ATM Q13315 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ CASP3 P42574 1/20 0.43
▸ SENP8 Q96LD8 1/20 0.43
▸ SENP7 Q9BQF6 1/20 0.43
▸ SENP6 Q9GZR1 1/20 0.43
▸ TSHR P16473 3/20 0.42
▸ POLB P06746 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ TP53 P04637 3/20 0.41
▸ HDAC1 Q13547 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27218808 0.92 RAB9A (0.50) SMN1; SMN2LMNAHTTNPC1RAB9A
SCHEMBL27218812 0.84 SIRT2 (0.52) SMN1; SMN2LMNAHTTNPC1RAB9A
SCHEMBL27218694 0.83 HDAC1 (0.49) SMN1; SMN2LMNAHTTNPC1RAB9A
SCHEMBL27218893 0.78 S1PR1 (0.47) SMN1; SMN2LMNANPC1RAB9AHDAC2
SCHEMBL27218848 0.78 SIRT2 (0.52) SMN1; SMN2LMNAHTTNPC1RAB9A
SCHEMBL31494429 0.77 ALDH1A1 (0.47) SMN1; SMN2LMNAHTTNPC1RAB9A
SCHEMBL27218682 0.76 S1PR1 (0.45) SMN1; SMN2LMNAHTTNPC1RAB9A
SCHEMBL27218738 0.73 RXFP1 (0.47) SMN1; SMN2LMNAHTTNPC1RAB9A
SCHEMBL27218894 0.72 NPC1 (0.48) SMN1; SMN2LMNAHTTNPC1RAB9A
SCHEMBL29808115 0.72 SMN1; SMN2 (0.49) SMN1; SMN2LMNAHTTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232448-B1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2025-05-07 — — EP disclosed
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 — — EP disclosed
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor Halo Therapeutics Ltd (GB) 2024-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor FFAR1, FFAR2, FFAR3 SMN1; SMN2 1802/4885LMNA 3526/4885HTT 4281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback